NVCR on Nasdaq

Novocure (Jersey)

Logo: novocure.com3

We are a global oncology company with a proprietary platform technology called Tumor Treating Fields ("TTFields"), which are electric fields that exert physical forces to kill cancer cells.5 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

2000Founded1

Compare with UFP Technologies, iRhythm Holdings, Inc. or Bioventus Inc., or pick any stock.

  • TickerNVCR on Nasdaq1
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersSaint Helier1
  • Websitewww.novocure.com
  • Business addressNo. 4 The Forum, Grenville Street, St. Helier4
  • Filer categoryLarge accelerated filer4

See how the biggest companies compare on our leaderboards

We are a global oncology company with a proprietary platform technology called Tumor Treating Fields ("TTFields"), which are electric fields that exert physical forces to kill cancer cells. Our therapy is delivered through a medical device. Our key priorities are to drive commercial adoption of Optune Gio ® , Optune Lua ® , and Optune Pax ® , our commercial TTFields therapy devices, obtain regulatory approval to market TTFields therapy devices in new indications, such as brain metastases from non-small cell lung cancer ("NSCLC"), and to advance clinical and product development programs intended to extend overall survival in some of the most aggressive forms of cancer.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

74.5%Gross margin6
-23.5%Operating margin6
-20.8%Net margin6
8.3%Revenue growth, 20256
-40.0%Return on equity7
0.57×Debt to equity7
-$75.7MFree cash flow6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Regions

United States brought in 59% of the revenue Novocure (Jersey) broke down this way in fiscal 2025.

  1. United States$385.6M659%down 2% from 2024
  2. Germany$79.4M612%up 22% from 2024
  3. France$76.2M612%up 37% from 2024
  4. Other International Markets$56.9M69%up 34% from 2024
  5. Japan$37.8M66%up 16% from 2024
  6. China$19.4M63%up 12% from 2024
Regions by year
Regions202320242025
United States$349.7M$391.8M$385.6M
Germany$60.2M$65.3M$79.4M
France$11.7M$55.7M$76.2M
Other International Markets$32.8M$42.5M$56.9M
Japan$31.7M$32.6M$37.8M
China$23.2M$17.4M$19.4M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue25¢$166.9M
  • Research and development34¢$224.5M
  • Other costs37¢$241.7M
  • Interest3¢$22.2M
  • Income tax0¢$23.0K

Out of $655.4M in revenue.6 The company lost money this year.

Financial statements

Revenue89101176$655.4M in 2025+87% since 2019
0$200.0M$400.0M$600.0M$800.0M2019: $351.3M$351.3M20192020: $494.4M$494.4M2020+41%2021: $535.0M$535.0M2021+8%2022: $537.8M$537.8M2022+1%2023: $509.3M$509.3M2023−5%2024: $605.2M$605.2M2024+19%2025: $655.4M$655.4M2025+8%
Gross profit89101176$488.5M in 2025+86% since 2019
0$200.0M$400.0M$600.0M2019: $262.7M$262.7M20192020: $387.9M$387.9M2020+48%2021: $420.2M$420.2M2021+8%2022: $423.0M$423.0M2022+1%2023: $381.1M$381.1M2023−10%2024: $468.0M$468.0M2024+23%2025: $488.5M$488.5M2025+4%
Operating income89101176-$153.8M in 2025+16727% since 2019
-$300.0M-$200.0M-$100.0M0$100.0M2019: -$914.0K-$914.0K20192020: $30.4M$30.4M20202021: -$44.3M-$44.3M20212022: -$89.5M-$89.5M2022+102%2023: -$232.9M-$232.9M2023+160%2024: -$170.5M-$170.5M2024−27%2025: -$153.8M-$153.8M2025−10%
Net income89101176-$136.2M in 2025+1784% since 2019
-$300.0M-$200.0M-$100.0M0$100.0M2019: -$7.2M-$7.2M20192020: $19.8M$19.8M20202021: -$58.4M-$58.4M20212022: -$92.5M-$92.5M2022+59%2023: -$207.0M-$207.0M2023+124%2024: -$168.6M-$168.6M2024−19%2025: -$136.2M-$136.2M2025−19%

Every line of the income statement as filed: the last 3 fiscal years, latest first.7

Period ending2025-12-312024-12-312023-12-31
Net revenues$655.4M$605.2M$509.3M
Cost of revenues$166.9M$137.2M$128.3M
Gross profit$488.5M$468.0M$381.1M
Research, development and clinical studies$224.5M$209.6M$223.1M
Sales and marketing$240.1M$239.1M$226.8M
General and administrative$177.7M$189.8M$164.1M
Total operating costs and expenses$642.3M$638.5M$613.9M
Operating income (loss)-$153.8M-$170.5M-$232.9M
Financial (expenses) income, net$17.6M$39.3M$41.1M
Total income (loss) before income taxes-$136.2M-$131.2M-$191.7M
Income tax-$23.0K$37.5M$15.3M
Net income (loss)-$136.2M-$168.6M-$207.0M
Basic net income (loss) per ordinary share (in usd per share)-$1.22-$1.56-$1.95
Diluted net income (loss) per ordinary share (in usd per share)-$1.22-$1.56-$1.95
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)111.5M shares107.8M shares106.4M shares
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)111.5M shares107.8M shares106.4M shares

Compare Novocure (Jersey) with another company

The story

Founded by Yoram Palti in 2000.1

Leadership

Who has led Novocure (Jersey), and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Asaf Danziger2015–2024
  2. Ashley Cordova2025–now

Chief financial officer

  1. Wilhelmus Cm Groenhuysen2015–2020
  2. Ashley Cordova2020–2024
  3. Christoph Brackmann2025–now

Chief operating officer

  1. Michael J. Ambrogi2015–2020
  2. Wilhelmus Cm Groenhuysen2020–2024
  3. Mukund Paravasthu2024–now
20052010201520202025
Board members and other officers (27)

Timeline

  1. Jan 3, 2025New chief executive Ashley Cordova becomes CEO14
  2. Oct 1, 2015New chief executive Asaf Danziger becomes CEO15
  3. 2000Founded Founded1

Filings

453 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 72 major events, 255 insider forms, 32 large holders, 74 other. The latest 20:

  1. Oct 1, 20268-K EDGAR
  2. Sep 9, 20268-K EDGAR
  3. Sep 1, 20268-K EDGAR
  4. Jul 23, 2026144 EDGAR
  5. Jul 23, 20268-K EDGAR
  6. Jul 23, 202610-Q EDGAR
  7. Jul 1, 20264 PRIMARY DOCUMENT EDGAR
  8. Jul 1, 20264 PRIMARY DOCUMENT EDGAR
  9. Jul 1, 20264 PRIMARY DOCUMENT EDGAR
  10. Jul 1, 20264 PRIMARY DOCUMENT EDGAR
  11. Jun 30, 20268-K EDGAR
  12. Jun 18, 20268-K EDGAR
  13. Jun 5, 20264 PRIMARY DOCUMENT EDGAR
  14. Jun 5, 20264 PRIMARY DOCUMENT EDGAR
  15. Jun 5, 20264 PRIMARY DOCUMENT EDGAR
  16. Jun 5, 20264 PRIMARY DOCUMENT EDGAR
  17. Jun 5, 20268-K EDGAR
  18. Jun 5, 20264 PRIMARY DOCUMENT EDGAR
  19. Jun 5, 20264 PRIMARY DOCUMENT EDGAR
  20. Jun 5, 20264 PRIMARY DOCUMENT EDGAR

The 453 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

147 open-market trades by officers, directors and large owners since October 2021: 3 buys and 144 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 4, 2026Leonard Frank XChief Executive OfficerSale34,273$17.93$614.5KForm 4
Jun 2, 2026Stafford KristinDirectorSale2,945$15.77$46.4KForm 4
Jun 2, 2026Ocean Allyson JDirectorSale2,945$15.77$46.4KForm 4
Jun 2, 2026Scannell Timothy JDirectorSale2,945$15.77$46.4KForm 4
Jun 2, 2026VERNON W ANTHONYDirectorSale2,945$15.77$46.4KForm 4
Jun 2, 2026Hung DavidDirectorSale2,945$15.77$46.4KForm 4
Jun 2, 2026LEUNG GABRIELDirectorSale2,945$15.77$46.4KForm 4
Jun 2, 2026HILLEMAN JERYL LDirectorSale2,945$15.77$46.4KForm 4
Mar 5, 2026Paravasthu MukundChief Operating OfficerSale43,246$13.77$595.5KForm 4
Mar 4, 2026Brackmann ChristophChief Financial OfficerSale6,412$13.31$85.3KForm 4
Mar 4, 2026Paravasthu MukundChief Operating OfficerSale5,377$13.31$71.6KForm 4
Mar 4, 2026Leupin NicolasFormer Chief Medical OfficerSale1,100$13.31$14.6KForm 4
Mar 4, 2026Puri Michal NathChief Human Resources OfficerSale1,100$13.31$14.6KForm 4
Mar 4, 2026Leonard Frank XChief Executive OfficerSale5,607$13.31$74.6KForm 4
Mar 4, 2026Weinberg UriChf Medical and Innovation OfrSale6,412$13.31$85.3KForm 4
Mar 3, 2026DOYLE WILLIAM FExecutive ChairmanSale71,887$12.98$933.1KForm 4
Mar 2, 2026Paravasthu MukundChief Operating OfficerSale408$13.49$5.5KForm 4
Mar 2, 2026Leonard Frank XChief Executive OfficerSale7,232$13.49$97.6KForm 4
Mar 2, 2026Weinberg UriChf Medical and Innovation OfrSale3,272$13.33$43.6KForm 4
Feb 27, 2026Paravasthu MukundChief Operating OfficerSale1,555$13.66$21.2KForm 4

All 147 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Members of Congress who traded it

3 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Jul 2, 2021Marie Newman, HouseBuy$15,001 - $50,000−170.1%Report
Jun 24, 2019Donna Shalala, HouseSale$1,001 - $15,000+238.0%Report
Jun 19, 2019Donna Shalala, HouseBuy$1,001 - $15,000−239.9%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
    Company websiteNovocure (Jersey) logo
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53